Opinion

Video

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

Author(s):

Rana R. McKay, MD,Neal Shore, MD, FACS

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Related Videos
Bradley C. Carthon, MD, PhD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Bertram Yuh, MD, MISM, MSHCPM
2 KOLs are featured in this series.
Related Content
Oliver Sartor, MD
October 23rd 2024

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Fred Saad, MD, FRCS
October 17th 2024

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Darolutamide Plus ADT in mHSPC: © vitanovski - stock.adobe.com
October 14th 2024

EU Approval Sought for Darolutamide Plus ADT for mHSPC

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.
October 12th 2024

The OncFive: Top Oncology Articles for the Week of 10/6